Grace Therapeutics, Inc.
GRCE
$3.02
$0.072.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.67% | -6.87% | -11.80% | -19.24% | 64.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.23% | 19.16% | -19.27% | -38.00% | -19.79% |
| Operating Income | -36.23% | -19.16% | 19.27% | 38.00% | 19.79% |
| Income Before Tax | 66.16% | 71.53% | 73.38% | 71.74% | -161.72% |
| Income Tax Expenses | 68.72% | 72.95% | 76.36% | 80.80% | -644.05% |
| Earnings from Continuing Operations | 65.52% | 71.18% | 72.70% | 69.71% | -124.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.52% | 71.18% | 72.70% | 69.71% | -124.83% |
| EBIT | -36.23% | -19.16% | 19.27% | 38.00% | 19.79% |
| EBITDA | -36.38% | -19.36% | 18.92% | 37.24% | 17.42% |
| EPS Basic | 76.81% | 81.02% | 79.39% | 74.34% | -137.34% |
| Normalized Basic EPS | 12.11% | 36.52% | 36.60% | 40.46% | 18.32% |
| EPS Diluted | 76.80% | 81.01% | 79.38% | 74.34% | -137.34% |
| Normalized Diluted EPS | 12.11% | 36.52% | 36.60% | 40.46% | 18.32% |
| Average Basic Shares Outstanding | 33.68% | 51.87% | 39.24% | 27.72% | 0.21% |
| Average Diluted Shares Outstanding | 33.68% | 51.87% | 39.24% | 27.72% | 0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |